---
schema_version: "secwatch.filing_event.v1"
accession: "0000950170-23-042419"
form_type: "8-K"
ticker: "KOD"
cik: "0001468748"
company_name: "Kodiak Sciences Inc."
filed_at: "2023-08-14T23:59:59+00:00"
generated_at: "2026-06-11T10:44:24.678161+00:00"
event_type: "earnings"
sentiment: "negative"
materiality_score: 0.9
calibrated_materiality_score: 0.9
confidence: "high"
source: SEC EDGAR
---

# Kodiak Sciences Q2 net loss $80.2M; winds down tarcocimab after Phase 3 DME miss

## Summary
- Q2 2023 net loss $80.2M ($1.53/sh) vs $90.6M ($1.74/sh) in Q2 2022.
- Cash and equivalents $378.7M at June 30, 2023.
- Phase 3 GLEAM and GLIMMER in DME missed primary efficacy endpoint; tarcocimab studies being wound down.
- Phase 3 DAYLIGHT in wet AMD met endpoint; no cataract imbalance observed.
- KSI-501 Phase 1 enrollment completed; exploring both unconjugated protein and bioconjugate forms.

## SEC filing metadata
- accession: 0000950170-23-042419
- form_type: 8-K
- ticker: KOD
- cik: 0001468748
- company_name: Kodiak Sciences Inc.
- filed_at: 2023-08-14T23:59:59+00:00
- event_type: earnings
- sentiment: negative
- materiality_score: 0.9
- calibrated_materiality_score: 0.9
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1468748/000095017023042419/0000950170-23-042419-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1468748/000095017023042419/kod-20230814.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0000950170-23-042419
- JSON: https://secwatch.observer/filing/0000950170-23-042419.json
- Plain text: https://secwatch.observer/filing/0000950170-23-042419.txt

## Key facts
- Earnings Releases
  Kodiak Sciences Inc. reported the quarter ended June 30, 2023 results: net income $80.2 million, or $1.53 per share on both a basic and diluted basis, EPS $1.53 per share on both a basic and diluted basis.
  - Period: the quarter ended June 30, 2023
  - Net income: $80.2 million, or $1.53 per share on both a basic and diluted basis
  - EPS: $1.53 per share on both a basic and diluted basis
  - Result: reported results
  source text: The net loss for the second quarter of 2023 was $80.2 million, or $1.53 per share on both a basic and diluted basis
  evidence_url: https://www.sec.gov/Archives/edgar/data/1468748/000095017023042419/0000950170-23-042419-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.